Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
Add more filters










Publication year range
1.
J Vis Exp ; (147)2019 05 17.
Article in English | MEDLINE | ID: mdl-31157788

ABSTRACT

Hyposalivation and xerostomia create chronic oral complications that decrease the quality of life in head and neck cancer patients who are treated with radiotherapy. Experimental approaches to understanding mechanisms of salivary gland dysfunction and restoration have focused on in vivo models, which are handicapped by an inability to systematically screen therapeutic candidates and efficiencies in transfection capability to manipulate specific genes. The purpose of this salivary gland organotypic culture protocol is to evaluate maximal time of culture viability and characterize cellular changes following ex vivo radiation treatment. We utilized immunofluorescent staining and confocal microscopy to determine when specific cell populations and markers are present during a 30-day culture period. In addition, cellular markers previously reported in in vivo radiation models are evaluated in cultures that are irradiated ex vivo. Moving forward, this method is an attractive platform for rapid ex vivo assessment of murine and human salivary gland tissue responses to therapeutic agents that improve salivary function.


Subject(s)
Models, Biological , Organ Culture Techniques/methods , Parotid Gland/growth & development , Parotid Gland/radiation effects , Submandibular Gland/growth & development , Submandibular Gland/radiation effects , Acinar Cells/metabolism , Animals , Apoptosis , Biomarkers/metabolism , Cell Proliferation , Female , Humans , Mice , Tissue Survival
2.
F1000Res ; 7: 1926, 2018.
Article in English | MEDLINE | ID: mdl-30687499

ABSTRACT

In the 21st Century, research is increasingly data- and computation-driven. Researchers, funders, and the larger community today emphasize the traits of openness and reproducibility. In March 2017, 13 mostly early-career research leaders who are building their careers around these traits came together with ten university leaders (presidents, vice presidents, and vice provosts), representatives from four funding agencies, and eleven organizers and other stakeholders in an NIH- and NSF-funded one-day, invitation-only workshop titled "Imagining Tomorrow's University." Workshop attendees were charged with launching a new dialog around open research - the current status, opportunities for advancement, and challenges that limit sharing. The workshop examined how the internet-enabled research world has changed, and how universities need to change to adapt commensurately, aiming to understand how universities can and should make themselves competitive and attract the best students, staff, and faculty in this new world. During the workshop, the participants re-imagined scholarship, education, and institutions for an open, networked era, to uncover new opportunities for universities to create value and serve society. They expressed the results of these deliberations as a set of 22 principles of tomorrow's university across six areas: credit and attribution, communities, outreach and engagement, education, preservation and reproducibility, and technologies. Activities that follow on from workshop results take one of three forms. First, since the workshop, a number of workshop authors have further developed and published their white papers to make their reflections and recommendations more concrete. These authors are also conducting efforts to implement these ideas, and to make changes in the university system.  Second, we plan to organise a follow-up workshop that focuses on how these principles could be implemented. Third, we believe that the outcomes of this workshop support and are connected with recent theoretical work on the position and future of open knowledge institutions.


Subject(s)
Universities , Career Choice , Community Participation , Community-Institutional Relations , Education , Humans , Information Technology , Research
3.
Front Nutr ; 3: 48, 2016.
Article in English | MEDLINE | ID: mdl-27843913

ABSTRACT

Replacing current refractory treatments for melanoma with new prevention and therapeutic approaches is crucial in order to successfully treat this aggressive cancer form. Melanoma develops from neural crest cells, which express tyrosinase - a key enzyme in the pigmentation pathway. The tyrosinase enzyme is highly active in melanoma cells and metabolizes polyphenolic compounds; tyrosinase expression thus makes feasible a target for polyphenol-based therapies. For example, quercetin (3,3',4',5,7-pentahydroxyflavone) is a highly ubiquitous and well-classified dietary polyphenol found in various fruits, vegetables, and other plant products including onions, broccoli, kale, oranges, blueberries, apples, and tea. Quercetin has demonstrated antiproliferative and proapoptotic activity in various cancer cell types. Quercetin is readily metabolized by tyrosinase into various compounds that promote anticancer activity; additionally, given that tyrosinase expression increases during tumorigenesis, and its activity is associated with pigmentation changes in both early- and late-stage melanocytic lesions, it suggests that quercetin can be used to target melanoma. In this review, we explore the potential of quercetin as an anti-melanoma agent utilizing and extrapolating on evidence from previous in vitro studies in various human malignant cell lines and propose a "four-focus area strategy" to develop quercetin as a targeted anti-melanoma compound for use as either a preventative or therapeutic agent. The four areas of focus include utilizing quercetin to (i) modulate cellular bioreduction potential and associated signaling cascades, (ii) affect transcription of relevant genes, (iii) regulate epigenetic processes, and (iv) develop effective combination therapies and delivery modalities/protocols. In general, quercetin could be used to exploit tyrosinase activity to prevent, and/or treat, melanoma with minimal additional side effects.

4.
PLoS One ; 9(12): e113183, 2014.
Article in English | MEDLINE | ID: mdl-25437438

ABSTRACT

The standard of care for head and neck cancer typically includes surgical resection of the tumor followed by targeted head and neck radiation. However depending on tumor location and stage, some cases may not require surgical resection while others may be treated with chemoradiation. Unfortunately, these radiation treatments cause chronic negative side effects for patients. These side effects are associated with damage to surrounding normal salivary gland tissue and include xerostomia, changes in taste and malnutrition. The underlying mechanisms of chronic radiation-induced salivary gland dysfunction are unknown, however, in rodent models persistently elevated proliferation is correlated with reduced stimulated salivary flow. The rapalogue, CCI-779, has been used in other cell systems to induce autophagy and reduce proliferation, therefore the aim of this study was to determine if CCI-779 could be utilized to ameliorate chronic radiation-induced salivary gland dysfunction. Four to six week old Atg5f/f; Aqp5-Cre, Atg5+/+; Aqp5-Cre and FVB mice were treated with targeted head and neck radiation. FVB mice were treated with CCI-779, chloroquine, or DMSO post-radiation. Stimulated salivary flow rates were determined and parotid and submandibular salivary gland tissues were collected for analyses. Mice with a defect in autophagy, via a conditional knockout of Atg5 in the salivary glands, display increased compensatory proliferation in the acinar cell compartment and hypertrophy at 24-72 hours following radiation. FVB mice treated with post-therapy CCI-779 have significant improvements in salivary gland physiology as determined by stimulated salivary flow rates, proliferation indices and amylase production and secretion. Consequently, post-radiation use of CCI-779 allows for improvement of salivary gland function and reestablishment of glandular homeostasis. As CCI-779 is already FDA approved for other uses, it could have a secondary use to alleviate the chronic side effects in head and neck cancer patients who have completed anti-tumor therapy.


Subject(s)
Parotid Gland/drug effects , Parotid Gland/physiology , Recovery of Function/drug effects , Recovery of Function/radiation effects , Sirolimus/analogs & derivatives , Submandibular Gland/drug effects , Submandibular Gland/physiology , Amylases/metabolism , Animals , Autophagy/drug effects , Autophagy/radiation effects , Autophagy-Related Protein 5 , Cell Proliferation/drug effects , Cell Proliferation/radiation effects , Head and Neck Neoplasms/radiotherapy , Mice , Microtubule-Associated Proteins/metabolism , Parotid Gland/cytology , Parotid Gland/radiation effects , Signal Transduction/drug effects , Signal Transduction/radiation effects , Sirolimus/pharmacology , Submandibular Gland/cytology , Submandibular Gland/radiation effects , TOR Serine-Threonine Kinases/metabolism , Time Factors
5.
Sci Rep ; 4: 5206, 2014 Jun 06.
Article in English | MEDLINE | ID: mdl-24903000

ABSTRACT

The current standard of care for head and neck cancer includes surgical resection of the tumor followed by targeted head and neck radiation. This radiotherapy results in a multitude of negative side effects in adjacent normal tissues. Autophagy is a cellular mechanism that could be targeted to ameliorate these side effects based on its role in cellular homeostasis. In this study, we utilized Atg5(f/f);Aqp5-Cre mice which harbor a conditional knockout of Atg5, in salivary acinar cells. These autophagy-deficient mice display increased radiosensitivity. Treatment of wild-type mice with radiation did not robustly induce autophagy following radiotherapy, however, using a model of preserved salivary gland function by IGF-1-treatment prior to irradiation, we demonstrate increased autophagosome formation 6-8 hours following radiation. Additionally, administration of IGF-1 to Atg5(f/f);Aqp5-Cre mice did not preserve physiological function. Thus, autophagy appears to play a beneficial role in salivary glands following radiation and pharmacological induction of autophagy could alleviate the negative side effects associated with therapy for head and neck cancer.


Subject(s)
Autophagy , Microtubule-Associated Proteins/physiology , Radiation Tolerance , Salivary Glands/pathology , Animals , Apoptosis/radiation effects , Autophagy-Related Protein 5 , Blotting, Western , Cell Proliferation/radiation effects , Cells, Cultured , Female , Gamma Rays , Immunoenzyme Techniques , Immunoprecipitation , Integrases/metabolism , Male , Mice , Mice, Knockout , Salivary Glands/metabolism , Salivary Glands/radiation effects
6.
J Med Internet Res ; 15(6): e125, 2013 Jun 24.
Article in English | MEDLINE | ID: mdl-23796439

ABSTRACT

BACKGROUND: Increasing an individual's awareness and understanding of their dietary habits and reasons for eating may help facilitate positive dietary changes. Mobile technologies allow individuals to record diet-related behavior in real time from any location; however, the most popular software applications lack empirical evidence supporting their efficacy as health promotion tools. OBJECTIVE: The purpose of this study was to test the feasibility and acceptability of a popular social media software application (Twitter) to capture young adults' dietary behavior and reasons for eating. A secondary aim was to visualize data from Twitter using a novel analytic tool designed to help identify relationships among dietary behaviors, reasons for eating, and contextual factors. METHODS: Participants were trained to record all food and beverages consumed over 3 consecutive days (2 weekdays and 1 weekend day) using their mobile device's native Twitter application. A list of 24 hashtags (#) representing food groups and reasons for eating were provided to participants to guide reporting (eg, #protein, #mood). Participants were encouraged to annotate hashtags with contextual information using photos, text, and links. User experience was assessed through a combination of email reports of technical challenges and a 9-item exit survey. Participant data were captured from the public Twitter stream, and frequency of hashtag occurrence and co-occurrence were determined. Contextual data were further parsed and qualitatively analyzed. A frequency matrix was constructed to identify food and behavior hashtags that co-occurred. These relationships were visualized using GMap algorithmic mapping software. RESULTS: A total of 50 adults completed the study. In all, 773 tweets including 2862 hashtags (1756 foods and 1106 reasons for eating) were reported. Frequently reported food groups were #grains (n=365 tweets), #dairy (n=221), and #protein (n=307). The most frequently cited reasons for eating were #social (activity) (n=122), #taste (n=146), and #convenience (n=173). Participants used a combination of study-provided hash tags and their own hash tags to describe behavior. Most rated Twitter as easy to use for the purpose of reporting diet-related behavior. "Maps" of hash tag occurrences and co-occurrences were developed that suggested time-varying diet and behavior patterns. CONCLUSIONS: Twitter combined with an analytical software tool provides a method for capturing real-time food consumption and diet-related behavior. Data visualization may provide a method to identify relationships between dietary and behavioral factors. These findings will inform the design of a study exploring the use of social media and data visualization to identify relationships between food consumption, reasons for engaging in specific food-related behaviors, relevant contextual factors, and weight and health statuses in diverse populations.


Subject(s)
Diet , Feeding Behavior , Internet , Adult , Feasibility Studies , Humans , Social Support
8.
PLoS One ; 7(12): e51363, 2012.
Article in English | MEDLINE | ID: mdl-23236487

ABSTRACT

BACKGROUND: Treatment of head and neck cancer with radiation often results in damage to surrounding normal tissues such as salivary glands. Permanent loss of function in the salivary glands often leads patients to discontinue treatment due to incapacitating side effects. It has previously been shown that IGF-1 suppresses radiation-induced apoptosis and enhances G2/M arrest leading to preservation of salivary gland function. In an effort to recapitulate the effects of IGF-1, as well as increase the likelihood of translating these findings to the clinic, the small molecule therapeutic Roscovitine, is being tested. Roscovitine is a cyclin-dependent kinase inhibitor that acts to transiently inhibit cell cycle progression and allow for DNA repair in damaged tissues. METHODOLOGY/PRINCIPAL FINDINGS: Treatment with Roscovitine prior to irradiation induced a significant increase in the percentage of cells in the G(2)/M phase, as demonstrated by flow cytometry. In contrast, mice treated with radiation exhibit no differences in the percentage of cells in G(2)/M when compared to unirradiated controls. Similar to previous studies utilizing IGF-1, pretreatment with Roscovitine leads to a significant up-regulation of p21 expression and a significant decrease in the number of PCNA positive cells. Radiation treatment leads to a significant increase in activated caspase-3 positive salivary acinar cells, which is suppressed by pretreatment with Roscovitine. Administration of Roscovitine prior to targeted head and neck irradiation preserves normal tissue function in mouse parotid salivary glands, both acutely and chronically, as measured by salivary output. CONCLUSIONS/SIGNIFICANCE: These studies suggest that induction of transient G(2)/M cell cycle arrest by Roscovitine allows for suppression of apoptosis, thus preserving normal salivary function following targeted head and neck irradiation. This could have an important clinical impact by preventing the negative side effects of radiation therapy in surrounding normal tissues.


Subject(s)
Apoptosis/drug effects , G2 Phase Cell Cycle Checkpoints/drug effects , Head and Neck Neoplasms/radiotherapy , Purines/pharmacology , Radiation Injuries, Experimental/prevention & control , Radiotherapy/adverse effects , Salivary Glands/drug effects , Analysis of Variance , Animals , Blotting, Western , Caspase 3 , Cyclin-Dependent Kinases/antagonists & inhibitors , DNA Primers/genetics , DNA Repair/physiology , Flow Cytometry , Mice , Proliferating Cell Nuclear Antigen , Purines/therapeutic use , Radiation Injuries, Experimental/drug therapy , Real-Time Polymerase Chain Reaction , Roscovitine , Salivary Glands/cytology , Salivary Glands/radiation effects
9.
Transl Oncol ; 5(3): 208-16, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22741040

ABSTRACT

Tumor cells grow in nutrient- and oxygen-deprived microenvironments and adapt to the suboptimal growth conditions by altering their metabolic pathways. This adaptation process commonly results in a tumor phenotype that displays a high rate of aerobic glycolysis and aggressive tumor characteristics. The glucose regulatory molecule, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), is a bifunctional enzyme that is central to glycolytic flux and is downstream of the metabolic stress sensor AMP-activated protein kinase (AMPK), which has been suggested to modulate glycolysis and possibly activate isoforms of PFKFB, specifically PFKFB3 expressed in tumor cells. Our results demonstrated that long-term low pH exposure induced AMPK activation, which resulted in the up-regulation of PFKFB3 and an increase in its serine residue phosphorylation. Pharmacologic activation of AMPK resulted in an increase in PFKFB3 as well as an increase in glucose consumption, whereas in contrast, inhibition of AMPK resulted in the down-regulation of PFKFB3 and decreased glycolysis. PFKFB3 overexpression in DB-1 tumor cells induced a high rate of glycolysis and inhibited oxygen consumption, confirming its role in controlling glycolytic flux. These results show that low pH is a physiological stress that can promote a glycolytic phenotype commonly associated with tumorigenesis. The implications are that the tumor microenviroment contributes to tumor growth and treatment resistance.

10.
Integr Cancer Ther ; 10(4): 328-40, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21196432

ABSTRACT

Melanoma is an aggressive tumor that expresses the pigmentation enzyme tyrosinase. Tyrosinase expression increases during tumorigenesis, which could allow for selective treatment of this tumor type by strategies that use tyrosinase activity. Approaches targeting tyrosinase would involve gene transcription or signal transduction pathways mediated by p53 in a direct or indirect manner. Two pathways are proposed for exploiting tyrosinase expression: (a) a p53-dependent pathway leading to apoptosis or arrest and (b) a reactive oxygen species-mediated induction of endoplasmic reticulum stress in p53 mutant tumors. Both strategies could use tyrosinase-mediated activation of quercetin, a dietary polyphenol that induces the expression of p53 and modulates reactive oxygen species. In addition to antitumor signaling properties, activation of quercetin could complement conventional cancer therapy by the induction of phase II detoxification enzymes resulting in p53 stabilization and transduction of its downstream targets. In conclusion, recent advances in tyrosinase enzymology, prodrug chemistry, and modern chemotherapeutics present an intriguing and selective multitherapy targeting system where dietary bioflavonoids could be used to complement conventional cancer treatments.


Subject(s)
Genes, p53 , Melanoma/enzymology , Monophenol Monooxygenase/metabolism , Neuroblastoma/enzymology , Quercetin/pharmacology , Skin Neoplasms/enzymology , Animals , Apoptosis , Genes, p53/drug effects , Humans , Melanoma/drug therapy , Melanoma/genetics , Monophenol Monooxygenase/genetics , Neuroblastoma/genetics , Quercetin/metabolism , Quercetin/pharmacokinetics , Reactive Oxygen Species/metabolism , Signal Transduction/drug effects , Signal Transduction/genetics , Skin Neoplasms/drug therapy , Skin Neoplasms/genetics
11.
BMC Cancer ; 10: 417, 2010 Aug 10.
Article in English | MEDLINE | ID: mdl-20698985

ABSTRACT

BACKGROUND: Radiotherapy for head and neck cancer results in severe and chronic salivary gland dysfunction in most individuals. This results in significant side effects including xerostomia, dysphagia, and malnutrition which are linked to significant reductions in patients' quality of life. Currently there are few xerostomia treatment approaches that provide long-term results without significant side effects. To address this problem we investigated the potential for post-therapeutic IGF-1 to reverse radiation-induced salivary gland dysfunction. METHODS: FVB mice were treated with targeted head and neck radiation and significant reductions in salivary function were confirmed 3 days after treatment. On days 4-8 after radiation, one group of mice was injected intravenously with IGF-1 while a second group served as a vehicle control. Stimulated salivary flow rates were evaluated on days 30, 60, and 90 and histological analysis was performed on days 9, 30, 60, and 90. RESULTS: Irradiated animals receiving vehicle injections have 40-50% reductions in stimulated salivary flow rates throughout the entire time course. Mice receiving injections of IGF-1 have improved stimulated salivary flow rates 30 days after treatment. By days 60-90, IGF-1 injected mice have restored salivary flow rates to unirradiated control mice levels. Parotid tissue sections were stained for amylase as an indicator of functioning acinar cells and significant reductions in total amylase area are detected in irradiated animals compared to unirradiated groups on all days. Post-therapeutic injections of IGF-1 results in increased amylase-positive acinar cell area and improved amylase secretion. Irradiated mice receiving IGF-1 show similar proliferation indices as untreated mice suggesting a return to tissue homeostasis. CONCLUSIONS: Post-therapeutic IGF-1 treatment restores salivary gland function potentially through normalization of cell proliferation and improved expression of amylase. These findings could aid in the rational design of therapy protocols or drugs for the treatment of radiation-induced salivary gland dysfunction in patients who have completed their anti-cancer therapies.


Subject(s)
Head and Neck Neoplasms/radiotherapy , Insulin-Like Growth Factor I/administration & dosage , Radiation Injuries, Experimental/prevention & control , Salivary Glands/drug effects , Salivary Glands/radiation effects , Xerostomia/prevention & control , Animals , Cell Proliferation/drug effects , Cell Proliferation/radiation effects , Female , Gamma Rays , Head and Neck Neoplasms/pathology , Mice , Prognosis , Radiation Injuries, Experimental/pathology , Salivary Glands/pathology , Xerostomia/etiology
12.
Nutr Rev ; 68(7): 418-28, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20591109

ABSTRACT

Quercetin is a unique dietary polyphenol because it can exert biphasic dose-responses on cells depending on its concentration. Cancer preventative effects of quercetin are observed at concentrations of approximately 1-40 microM and are likely mediated by quercetin's antioxidant properties. Pro-oxidant effects are present at cellular concentrations of 40-100 microM. However, at higher concentrations, many novel pathways in addition to ROS contribute to its effects. The potent bioactivity of quercetin has led to vigorous study of this compound and revealed numerous pathways that could interact synergistically to prevent or treat cancer. The effect of intake and concentration on emerging pathways and how they may interact are discussed in this review.


Subject(s)
Antioxidants/pharmacology , Antioxidants/therapeutic use , Neoplasms/diet therapy , Neoplasms/prevention & control , Quercetin/pharmacology , Quercetin/therapeutic use , Animals , Antioxidants/adverse effects , Antioxidants/pharmacokinetics , Dietary Supplements , Dose-Response Relationship, Drug , Humans , Osmolar Concentration , Oxidants/adverse effects , Oxidants/pharmacokinetics , Oxidants/pharmacology , Oxidants/therapeutic use , Quercetin/adverse effects , Quercetin/pharmacokinetics
13.
BMC Cancer ; 10: 282, 2010 Jun 11.
Article in English | MEDLINE | ID: mdl-20540768

ABSTRACT

BACKGROUND: The alkylating agent dacarbazine (DTIC) has been used in the treatment of melanoma for decades, but when used as a monotherapy for cancer only moderate response rates are achieved. Recently, the clinical use of temozolomide (TMZ) has become the more commonly used analog of DTIC-related oral agents because of its greater bioavailability and ability to cross the blood brain barrier. The response rates achieved by TMZ are also unsatisfactory, so there is great interest in identifying compounds that could be used in combination therapy. We have previously demonstrated that the bioflavonoid quercetin (Qct) promoted a p53-mediated response and sensitized melanoma to DTIC. Here we demonstrate that Qct also sensitizes cells to TMZ and propose a mechanism that involves the modulation of a truncated p53 family member, deltaNp73. METHODS: DB-1 melanoma (p53 wildtype), and SK Mel 28 (p53 mutant) cell lines were treated with TMZ (400 microM) for 48 hrs followed by Qct (75 microM) for 24 hrs. Cell death was determined by Annexin V-FITC staining and immunocytochemical analysis was carried out to determine protein translocation. RESULTS: After treatment with TMZ, DB-1 cells demonstrated increased phosphorylation of ataxia telangiectasia mutated (ATM) and p53. However, the cells were resistant to TMZ-induced apoptosis and the resistance was associated with an increase in nuclear localization of deltaNp73. Qct treatment in combination with TMZ abolished drug insensitivity and caused a more than additive induction of apoptosis compared to either treatment alone. Treatment with Qct, caused redistribution of deltaNp73 into the cytoplasm and nucleus, which has been associated with increased p53 transcriptional activity. Knockdown of deltaNp73 restored PARP cleavage in the TMZ treated cells, confirming its anti-apoptotic role. The response to treatment was predominantly p53 mediated as the p53 mutant SK Mel 28 cells showed no significant enhancement of apoptosis. CONCLUSION: This study demonstrates that Qct can sensitize cells to TMZ and that the mechanisms of sensitization involve modulation of p53 family members.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Apoptosis/drug effects , DNA-Binding Proteins/metabolism , Dacarbazine/analogs & derivatives , Drug Resistance, Neoplasm/drug effects , Melanoma/metabolism , Nuclear Proteins/metabolism , Quercetin/pharmacology , Tumor Suppressor Proteins/metabolism , Ataxia Telangiectasia Mutated Proteins , Cell Cycle Proteins/metabolism , Cell Line, Tumor , DNA Damage , DNA-Binding Proteins/genetics , Dacarbazine/pharmacology , Dose-Response Relationship, Drug , Humans , Melanins/biosynthesis , Melanoma/genetics , Melanoma/pathology , Mutation , Nuclear Proteins/genetics , Phosphorylation , Poly(ADP-ribose) Polymerases/metabolism , Protein Serine-Threonine Kinases/metabolism , Protein Transport , RNA Interference , Temozolomide , Time Factors , Tumor Protein p73 , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Proteins/genetics
14.
Int J Radiat Oncol Biol Phys ; 75(3): 854-61, 2009 Nov 01.
Article in English | MEDLINE | ID: mdl-19801101

ABSTRACT

PURPOSE: The tumor growth kinetics of the human LoVo colorectal xenograft model was assessed in response to vandetanib, an orally available receptor tyrosine kinase inhibitor, radiotherapy (RT), or irinotecan (CPT-11), as single therapies and in combination. METHODS AND MATERIALS: LoVo cells were injected subcutaneously into the right hind limb (5 x 10(6) cells in 100 microL phosphate-buffered saline) of athymic NCR NUM mice and tumors were grown to a volume of 200-300 mm(3) before treatment. Vandetanib was administered at 50 mg/kg daily orally for 14 days starting on Day 1. RT was given as three fractions (3 x 3 Gy) on Days 1, 2, and 3. CPT-11 was given at 15 mg/kg intraperitoneally on Days 1 and 3. Tumor volumes were measured on a daily basis and calculated by measuring tumor diameters with digital calipers in two orthogonal dimensions. RESULTS: All three single treatments (vandetanib, CPT-11, and radiation) significantly slowed LoVo colorectal tumor growth. Vandetanib significantly increased the antitumor effects of CPT-11 and radiation when given in combination with either of these treatments. These treatment combinations resulted in a slow tumor growth rate during the 2 weeks of vandetanib administration. The triple combination of vandetanib, CPT-11, and radiation produced the most marked improvement in response as observed by measurable shrinkage of tumors during the first week of treatment. CONCLUSIONS: The tumor growth delay kinetics observed in this study of the LoVo colorectal model suggest concurrent and sustained post-sequencing of vandetanib with cytotoxic therapy may be beneficial in tumors of this type.


Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Camptothecin/analogs & derivatives , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/radiotherapy , Piperidines/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Quinazolines/therapeutic use , Angiogenesis Inhibitors/therapeutic use , Animals , Camptothecin/therapeutic use , Colorectal Neoplasms/pathology , Combined Modality Therapy/methods , Dose Fractionation, Radiation , ErbB Receptors , Humans , Irinotecan , Mice , Mice, Nude , Tumor Burden , Xenograft Model Antitumor Assays
15.
Nutr Cancer ; 61(3): 322-31, 2009.
Article in English | MEDLINE | ID: mdl-19373605

ABSTRACT

Epidemiological and clinical data suggest that selenium may prevent prostate cancer; however, the cellular effects of selenium in malignant prostate cells are not well understood. We previously reported that the activity of the tumor suppressor PTEN is modulated by thioredoxin (Trx) in a RedOx-dependent manner. In this study, we demonstrated that the activity of Trx reductase (TR) is increased by sevenfold in the human prostate cancer cell line, DU-145, after 5 days of sodium selenite (Se) treatment. The treatment of DU-145 cells with increasing concentrations of Se induced an increase in PTEN lipid phosphatase activity by twofold, which correlated with a decrease in phospho-ser(473)-Akt, and an increase in phospho-Ser(370)-PTEN levels. Se also increased casein kinase-2 (CK2) activity; and the use of apigenin, an inhibitor of CK2, revealed that the regulation of the tumor suppressor PTEN by Se may be achieved via both the Trx-TR system and the RedOx control of the kinase involved in the regulation of PTEN activity.


Subject(s)
PTEN Phosphohydrolase/metabolism , Prostatic Neoplasms/enzymology , Sodium Selenite/pharmacology , Tumor Suppressor Proteins/analysis , Casein Kinase II/physiology , Cell Line, Tumor , Glutathione/metabolism , Humans , Male , Phosphorylation , Prostatic Neoplasms/pathology , Proto-Oncogene Proteins c-akt/metabolism , Thioredoxin-Disulfide Reductase/metabolism , Thioredoxins/metabolism
16.
Int J Radiat Oncol Biol Phys ; 73(2): 523-9, 2009 Feb 01.
Article in English | MEDLINE | ID: mdl-19147016

ABSTRACT

PURPOSE: Radiotherapy for head-and-neck cancer causes adverse secondary side effects in the salivary glands and results in diminished quality of life for the patient. A previous in vivo study in parotid salivary glands demonstrated that targeted head-and-neck irradiation resulted in marked increases in phosphorylated p53 (serine(18)) and apoptosis, which was suppressed in transgenic mice expressing a constitutively active mutant of Akt1 (myr-Akt1). METHODS AND MATERIALS: Transgenic and knockout mouse models were exposed to irradiation, and p53-mediated transcription, apoptosis, and salivary gland dysfunction were analyzed. RESULTS: The proapoptotic p53 target genes PUMA and Bax were induced in parotid salivary glands of mice at early time points after therapeutic radiation. This dose-dependent induction requires expression of p53 because no radiation-induced expression of PUMA and Bax was observed in p53-/- mice. Radiation also induced apoptosis in the parotid gland in a dose-dependent manner, which was p53 dependent. Furthermore, expression of p53 was required for the acute and chronic loss of salivary function after irradiation. In contrast, apoptosis was not induced in p53-/- mice, and their salivary function was preserved after radiation exposure. CONCLUSIONS: Apoptosis in the salivary glands after therapeutic head-and-neck irradiation is mediated by p53 and corresponds to salivary gland dysfunction in vivo.


Subject(s)
Apoptosis/radiation effects , Salivary Glands/radiation effects , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Proteins/metabolism , bcl-2-Associated X Protein/metabolism , Animals , Apoptosis/physiology , Apoptosis Regulatory Proteins , Caspase 3/metabolism , Dose-Response Relationship, Radiation , Enzyme Activation , Female , Genes, p53/genetics , Membrane Proteins/metabolism , Mice , Mice, Knockout , Mice, Transgenic , Parotid Gland/metabolism , Parotid Gland/radiation effects , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolism , RNA, Messenger/metabolism , Salivary Glands/metabolism
17.
Cell Oncol ; 30(5): 371-87, 2008.
Article in English | MEDLINE | ID: mdl-18791269

ABSTRACT

Dacarbazine (DTIC) has been used for the treatment of melanoma for decades. However, monotherapy with this chemotherapeutic agent results only in moderate response rates. To improve tumor response to DTIC current clinical trials in melanoma focus on combining a novel targeted agent with chemotherapy. Here, we demonstrate that tyrosinase which is commonly overexpressed in melanoma activates the bioflavonoid quercetin (Qct) and promotes an ataxia telangiectasia mutated (ATM)-dependent DNA damage response. This response sensitizes melanoma cells that overexpress tyrosinase to DTIC. In DB-1 melanoma cells that overexpress tyrosinase (Tyr(+) cells), the threshold for phosphorylation of ATM and p53 at serine 15 was observed at a low dose of Qct (25 microM) when compared to the mock transfected pcDNA3 cells, which required a higher dose (75 microM). Both pcDNA3 and Tyr(+) DB-1 cells demonstrated similar increases in phosphorylation of p53 at other serine sites, but in the Tyr(+) cells, DNApk expression was found to be reduced compared to control cells, indicating a shift towards an ATM-mediated response. The DB-1 control cells were resistant to DTIC, but were sensitized to apoptosis with high dose Qct, while Tyr(+) cells were sensitized to DTIC with low or high dose Qct. Qct also sensitized SK Mel 5 (p53 wildtype) and 28 (p53 mutant) cells to DTIC. However, when SK Mel 5 cells were transiently transfected with tyrosinase and treated with Qct plus DTIC, SK Mel 5 cells demonstrated a more than additive induction of apoptosis. Therefore, this study demonstrates that tyrosinase overexpression promotes an ATM-dependent p53 phosphorylation by Qct treatment and sensitizes melanoma cells to dacarbazine. In conclusion, these results suggest that Qct or Qct analogues may significantly improve DTIC response rates in tumors that express tyrosinase.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Dacarbazine/pharmacology , Melanoma, Experimental/enzymology , Monophenol Monooxygenase/metabolism , Quercetin/pharmacology , Tumor Suppressor Protein p53/metabolism , Antineoplastic Agents, Alkylating/pharmacology , Antioxidants/pharmacology , Apoptosis/drug effects , Ataxia Telangiectasia Mutated Proteins , Blotting, Western , Cell Cycle Proteins/metabolism , Cell Line, Tumor , DNA-Binding Proteins/metabolism , Humans , Melanoma, Experimental/drug therapy , Monophenol Monooxygenase/genetics , Phosphorylation , Protein Serine-Threonine Kinases/metabolism , Reactive Oxygen Species , Transfection , Tumor Suppressor Proteins/metabolism
18.
Nutr Cancer ; 59(2): 258-68, 2007.
Article in English | MEDLINE | ID: mdl-18001220

ABSTRACT

Tyrosinase is expressed in melanoma cells and catalyzes the formation of 3,3',4',5,7-pentahydroxyflavone (quercetin) into reactive quinone species and subsequent glutathionyl adducts. Therefore, we examined the effect of quercetin metabolism on the glutathione (GSH) bioreduction pathway and cell viability in DB-1 melanoma cells that express varying levels of tyrosinase (Tyr+). In a cell-free system, GSH was significantly decreased by quercetin, which coincided with the formation of glutathionyl adducts. In Tyr+ clones, quercetin decreased bioreduction capacity and increased reactive oxygen species (ROS) to a greater degree compared to control cells. The antioxidant/electrophile response element-induced enzymes, glutathione-S-transferase (GST), and nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 were expressed at high levels in Tyr+ cells and contributed to pro-oxidant quercetin metabolism. The basal level of ROS and apoptosis was higher in Tyr+ cells and were selectively increased after exposure to quercetin. The increase in apoptosis following quercetin exposure was p53/Bax mediated and correlated with a decrease in GST-driven bioreduction capacity and an increase in ROS. In conclusion, quercetin can selectively sensitize Tyr+ expressing melanoma cells to apoptosis and may serve as an adjuvant to chemotherapy by enhancing cell death and interfering with GST-mediated drug resistance.


Subject(s)
Apoptosis/drug effects , Enzyme Activation/drug effects , Gene Expression Regulation, Enzymologic , Melanoma/enzymology , Monophenol Monooxygenase/metabolism , Quercetin/pharmacology , Cell Line, Tumor , Cell Survival , Dose-Response Relationship, Drug , Gene Expression Regulation, Enzymologic/drug effects , Glutathione/metabolism , Humans , Melanocytes/drug effects , Melanocytes/enzymology , Reactive Oxygen Species/metabolism
19.
Int J Radiat Oncol Biol Phys ; 67(5): 1526-37, 2007 Apr 01.
Article in English | MEDLINE | ID: mdl-17234361

ABSTRACT

PURPOSE: To determine the effect of vascular endothelial growth factor VEGF Trap (Regeneron Pharmaceuticals, Tarrytown, NY), a humanized soluble vascular endothelial growth factor (VEGF) receptor protein, and radiation (RT) on tumor growth in U87 glioblastoma xenografts in nude mice. METHODS AND MATERIALS: U87 cell suspensions were implanted subcutaneously into hind limbs of nude mice. VEGF Trap (2.5-25 mg/kg) was administered every 3 days for 3 weeks alone or in combination with a single dose of 10 Gy or fractionated RT (3 x 5 Gy). In addition, three scheduling protocols for VEGF Trap plus fractionated RT were examined. RESULTS: Improved tumor control was seen when RT (either single dose or fractionated doses) was combined with the lowest dose of VEGF Trap (2.5 mg/kg). Scheduling did not significantly affect the efficacy of combined therapy. Although high-dose VEGF Trap (10 mg/kg or 25 mg/kg) significantly reduced tumor growth over that of RT alone, there was no additional benefit to combining high-dose VEGF Trap with RT. CONCLUSIONS: Vascular endothelial growth factor Trap plus radiation is clearly better than radiation alone in a U87 subcutaneous xenograft model. Although high doses of VEGF Trap alone are highly efficacious, it is unclear whether such high doses can be used clinically without incurring normal tissue toxicities. Thus, information on lower doses of VEGF Trap and ionizing radiation is of clinical relevance.


Subject(s)
Angiogenesis Inhibitors/administration & dosage , Glioblastoma/radiotherapy , Neoplasm Proteins/antagonists & inhibitors , Vascular Endothelial Growth Factors/antagonists & inhibitors , Animals , Combined Modality Therapy , Drug Screening Assays, Antitumor , Fluorodeoxyglucose F18 , Glioblastoma/blood supply , Glioblastoma/drug therapy , Glioblastoma/metabolism , Mice , Mice, Nude , Microcirculation/drug effects , Microcirculation/radiation effects , Neoplasm Proteins/metabolism , Radiation Tolerance/drug effects , Radiopharmaceuticals , Radiotherapy Dosage , Recombinant Fusion Proteins/administration & dosage , Transplantation, Heterologous , Vascular Endothelial Growth Factors/metabolism
20.
Curr Protoc Pharmacol ; Chapter 14: Unit 14.7, 2007 Sep.
Article in English | MEDLINE | ID: mdl-21948166

ABSTRACT

This unit (1) provides background into understanding how agents that target specific molecules or receptors (molecular-targeted agents), in particular, agents affecting the tumor vasculature (perivasculature network in tumors), interact with and modify radiation therapy; (2) details factors affecting interpretation of results in murine tumor model experiments utilizing radiation therapy and drug combinations; and (3) provides specific protocols for the application of radiation therapy, both alone and in combination with chemotherapy and/or molecular-targeted agents.


Subject(s)
Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/radiotherapy , Angiogenesis Inhibitors/therapeutic use , Animals , Cell Hypoxia , Disease Models, Animal , Fluorodeoxyglucose F18 , Humans , Mice , Mice, SCID , Neoplasms, Experimental/metabolism , Oxygen Consumption , Xenograft Model Antitumor Assays
SELECTION OF CITATIONS
SEARCH DETAIL
...